EBV抗体和EBV-DNA在鼻咽癌诊断及分期的研究  

Assessment of EBV antibodies and EBV- DNA in the diagnosis and stages of nasopharyngeal carcinoma

作　　者：俞霞[1] 季明芳[1] 程伟民[1] 黄玉玲[1] 李付贵[1] 

机构地区：[1]中山大学附属中山医院中山市肿瘤研究所,广东省中山市528400

出　　处：《中国肿瘤临床》2016年第15期650-654,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81572062)资助~~

摘　　要：目的:评估EBNA1/Ig A、Zta/Ig A、VCA/Ig A和EBV-DNA对不同分期鼻咽癌的诊断效能,探讨各指标阳性率与鼻咽癌分期的关系。方法:收集2010年3月至2015年9月中山大学附属中山医院收治的初诊鼻咽癌患者152例,健康体检者675例。采用酶联免疫吸附法(ELISA)检测血清EBNA1/Ig A、Zta/Ig A和VCA/Ig A抗体ROD值,荧光定量PCR(fluorescence quantitative PCR,FQPCR)检测血浆EBV-DNA水平。比较单独和联合应用EBV标记物对各期鼻咽癌的诊断效能,同时分析各指标阳性率与鼻咽癌分期的关系。结果:鼻咽癌患者EBNA1/Ig A、Zta/Ig A、VCA/Ig A和EBV-DNA阳性率显著高于健康体检者(P<0.01)。EBNA1/Ig A在早期鼻咽癌表达相对较高,灵敏度为77.8%,而EBV-DNA在晚期鼻咽癌的灵敏度最高为88.8%,两者特异度均在96%以上。联合检测中EBNA1/Ig A并联EBV-DNA检测的灵敏度为92.1%(早期为82.5%、晚期为98.9%),特异度为96.9%。EBV-DNA阳性率与鼻咽癌临床分期和N分期呈正相关,Zta/Ig A阳性率与N分期呈正相关(P<0.01)。结论:在无症状人群中进行鼻咽癌筛查,单项指标首选EBNA1/Ig A。晚期患者的辅助诊断则推荐EBV-DNA。两者并联检测可进一步提高鼻咽癌诊断效能。EBV-DNA是鼻咽癌分期和病情监测的重要指标,Zta/Ig A可间接反映淋巴结转移情况,有望对患者病情评估起到参考作用。Objective：To evaluate the efficacy of Epstein-Barr nuclear antigen 1/immunoglobulin A （EBNA1/IgA）, BamH1 Z transactivator/IgA （Zta/IgA）, capsid antigen/IgA （VCA/IgA）, and Epstein-Barr virus deoxyribonucleic acid （EBV-DNA） in detecting different stages of na-sopharyngeal carcinoma （NPC）. The relationship between the EBV markers and stages of NPC was also analyzed. Methods：Blood sam-ples of 152 untreated patients with NPC and 675 healthy subjects were collected.ELISA was used to detect the serum levels of EBNA1/IgA, Zta/IgA, and VCA/IgA. Fluorescence quantitative PCR （FQ-PCR） was used to detect the plasma levels of EBV-DNA. ROC and correla-tion analyses were employed to assess the detection assays for NPC diagnosis. The positive rates of EBV markers in NPC patients in dif-ferent stages were analyzed statistically. Results： The positive rates of EBNA1/IgA, Zta/IgA, VCA/IgA, and EBV-DNA in NPC patients were higher than those in the healthy individuals. The expression of EBNA1/IgA was relatively high in early NPC. The sensitivity of EB-NA1/IgA was 77.8%. In advanced NPC, the level of EBV-DNA was high, and the sensitivity of EBV-DNA was 88.8%. The specificity of EBV-DNA and EBNA1/IgA could reach more than 96%. The combination of EBV-DNA and EBNA1/IgA showed the best diagnostic value, with a sensitivity of 92.1%（early stage 82.5%, advanced stage 98.9%） and a specificity of 96.9%. The positive rates of EBV-DNA were positively associated with the NPC clinic stage and N stage. The positives rates of Zta/IgA were positively associated with the NPC N stage. Conclusion：The best single index for NPC screening in an asymptomatic population is EBNA1/IgA. EBV–DNA is an ideal index for auxiliary diagnostics of advanced NPC. The combination of EBV-DNA and EBNA1/IgA shows the best diagnostic value. EBV-DNA is an important index in the stage and illness monitoring of NPC. Zta/IgA can indirectly reflect the character of lymph node metastasis, and it may be useful in assessment of NPC surveillance.

关 键 词：鼻咽癌 EBV抗体 EBV-DNA 诊断 分期 

分 类 号：R739.63[医药卫生—肿瘤]